176905 Anthrax Protective Antigen, Bacillus anthracis, Recombinant, B. anthracis - Calbiochem

176905
가격을 검색할 수 없습니다
Minimum Quantity needs to be mulitiple of
가격 문의 추가 정보
()이 할인됨
 
가격 문의
재고 없음재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service
      가격 및 재고 조회

      개요

      Replacement Information

      주요 사양표

      가격 및 재고여부

      카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
      176905-100UGCN
      재고 정보 검색...
      재고 없음재고 없음
      예상 출고 가능일 
      단종품
      제한된 수량 가능
      재고여부 확인
        Remaining: will advise
          Remaining: will advise
          추천사항
          고객 서비스로 문의
          Contact Customer Service

          Plastic ampoule 100 μg
          가격 검색...
          가격을 검색할 수 없습니다
          Minimum Quantity needs to be mulitiple of
          가격 문의 추가 정보
          ()이 할인됨
           
          가격 문의
          Description
          OverviewRecombinant, Bacillus anthracis anthrax protective antigen expressed in a specialized strain of B. anthracis. One of the three protein components of Anthrax toxin, protective antigen (PA) is the central moiety that mediates the entry of lethal factor and edema factor into the target cell. PA binds to the cell surface via a type I membrane protein with a von Willebrand factor A domain called anthrax toxin receptor. After proteolytic activation to a 63 kDa fragment, PA self-associates to form a heptameric cation-selective, voltage-gated membrane channel.
          Catalogue Number176905
          Brand Family Calbiochem®
          References
          ReferencesMogridge, J., et al. 2002. Biochemistry 41, 1079.
          Nassi, S., et al. 2002. Biochemistry 41, 1445.
          Ahuja, N., et al. 2001. Biochem. Biophys. Res. Commun. 286, 6.
          Bradley, K.A., et al. 2001. Nature 414, 225.
          Brossier, F., and Mock, M. 2001. Toxicon 39, 1747.
          Product Information
          ATP CompetitiveN
          FormLyophilized
          FormulationLyophilized from 50 mM NaCl, 5 mM HEPES, pH 7.5.
          ReversibleN
          Quality LevelMQ100
          Applications
          ApplicationAnthrax Protective Antigen, Bacillus anthracis, Recombinant, is the protective antigen that mediates the entry of anthrax lethal factor and edema factor into the target cell.
          Biological Information
          Primary TargetType I membrane protein with a von Willebrand factor A domain called anthrax toxin receptor
          PuritySingle major band by SDS-PAGE. Several smaller minor components are apparent that may represent cleavage fragments of the PA.
          Physicochemical Information
          Cell permeableN
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 6 months at -20°C.
          End use certificateY
          Canadian export regulations Due to the country and/or U.S. state of origin of the animal material used in this product, this product may not be exported to Canada.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Anthrax Protective Antigen, Bacillus anthracis, Recombinant, B. anthracis - Calbiochem MSDS

          타이틀

          물질안전보건자료(MSDS) 

          Anthrax Protective Antigen, Bacillus anthracis, Recombinant, B. anthracis - Calbiochem Certificates of Analysis

          TitleLot Number
          176905

          References

          참고문헌 보기
          Mogridge, J., et al. 2002. Biochemistry 41, 1079.
          Nassi, S., et al. 2002. Biochemistry 41, 1445.
          Ahuja, N., et al. 2001. Biochem. Biophys. Res. Commun. 286, 6.
          Bradley, K.A., et al. 2001. Nature 414, 225.
          Brossier, F., and Mock, M. 2001. Toxicon 39, 1747.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision15-April-2008 RFH
          DescriptionRecombinant, Bacillus anthracis anthrax protective antigen expressed in a special strain of B. anthracis. One of three protein components of anthrax toxin produced by the pathogenic bacterium, Bacillus anthracis. Central moiety that mediates entry of lethal factor (LF) and edema factor (EF) into the target cell. PA83 binds to the cell surface via a type I membrane receptor with a von Willebrand factor A domain, known as anthrax toxin receptor. PA83 is proteolytically activated in vivo by a furin-like protease to produce a 63 kDa protein (PA63). PA63 self-associates to form a heptameric, cation-selective, voltage-gated, membrane channel that subsequently binds to LF and/or EF. Cleavage of the 20 kDa fragment from PA83 is necessary for binding of protective antigen to LF and EF.
          FormLyophilized
          FormulationLyophilized from 50 mM NaCl, 5 mM HEPES, pH 7.5.
          PuritySingle major band by SDS-PAGE. Several smaller minor components are apparent that may represent cleavage fragments of the PA.
          SolubilityReconstitute in 100 µl sterile, distilled H₂O to yield a final concentration of 1 mg/ml.
          Storage +2°C to +8°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Avoid freeze/thaw cycles of solutions. Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesMogridge, J., et al. 2002. Biochemistry 41, 1079.
          Nassi, S., et al. 2002. Biochemistry 41, 1445.
          Ahuja, N., et al. 2001. Biochem. Biophys. Res. Commun. 286, 6.
          Bradley, K.A., et al. 2001. Nature 414, 225.
          Brossier, F., and Mock, M. 2001. Toxicon 39, 1747.